Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James H Lewis

Showing results (1-10 of 99) with videos related to

Pageof 10
Sort By:
Drug Safety|June 14, 2011
The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapiesJames H Lewis
Gastroenterology & Hepatology|August 31, 2012
The adaptive response (drug tolerance) helps to prevent drug-induced liver injuryJames H Lewis
The American Journal of Gastroenterology|August 4, 2012
How the FDA handles GI drug safetyJames H Lewis
Pharmacoepidemiology and Drug Safety|January 31, 2006
'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspectiveJames H Lewis
American Family Physician|March 30, 2007
Relationship between certain medications and cirrhosisJames H Lewis
Expert Review of Gastroenterology & Hepatology|February 9, 2010
Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspectiveJames H Lewis
Buffalo Medical Journal|March 8, 2023
The Cancer CampaignJames H Lewis
Current Opinion in Gastroenterology|October 13, 2006
Drug-induced liver diseaseJames H Lewis
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 18, 2014
Drug-induced liver injury, dosage, and drug disposition: is idiosyncrasy really unpredictable?James H Lewis
Digestive Diseases and Sciences|July 11, 2014
Prescribing a statin to a cirrhotic patient to reduce hepatic decompensation and improve survival: impossible you say?James H Lewis
Pageof 10

Showing results (1-10 of 99) with videos related to

Sort By:
Pageof 10
Drug Safety|June 14, 2011
The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapiesJames H Lewis
Gastroenterology & Hepatology|August 31, 2012
The adaptive response (drug tolerance) helps to prevent drug-induced liver injuryJames H Lewis
The American Journal of Gastroenterology|August 4, 2012
How the FDA handles GI drug safetyJames H Lewis
Pharmacoepidemiology and Drug Safety|January 31, 2006
'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspectiveJames H Lewis
American Family Physician|March 30, 2007
Relationship between certain medications and cirrhosisJames H Lewis
Expert Review of Gastroenterology & Hepatology|February 9, 2010
Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspectiveJames H Lewis
Buffalo Medical Journal|March 8, 2023
The Cancer CampaignJames H Lewis
Current Opinion in Gastroenterology|October 13, 2006
Drug-induced liver diseaseJames H Lewis
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 18, 2014
Drug-induced liver injury, dosage, and drug disposition: is idiosyncrasy really unpredictable?James H Lewis
Digestive Diseases and Sciences|July 11, 2014
Prescribing a statin to a cirrhotic patient to reduce hepatic decompensation and improve survival: impossible you say?James H Lewis
Pageof 10